Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Acute Myeloid Leukemia (AML)

 

Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients (2572)
A Phase I/II Study of Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients with Untreated Acute Myeloid Leukemia

Investigator: John Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia (AML);    Status: Recruiting;   Study ID: NCT01756677

Liposomal Cytarabine-Daunorubicin CPX-351 for Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (2642)
Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults With Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality

Investigator: Roland B. Walter, MD;   Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT01804101

CPX-351 Versus 7+3 for Older Patients (2651)
Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) AML

Investigator: John Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01696084

Chemotherapy for MDS Patients Prior Donor Stem Cell Transplant (2661)
Initial cytoreductive therapy for myelodysplastic syndrome prior to allogeneic hematopoietic cell transplantation (the ICT-HCT Study)

Investigator: Bart Scott, MD;   Conditions: Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD);    Status: Recruiting;   Study ID: NCT01812252

Safety Study of SGN-CD33A Acute Myeloid Leukemia (2690)
A Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia (AML);    Status: Recruiting;   Study ID: NCT01902329

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride for Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) (2734)
A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD);    Status: Recruiting;   Study ID: NCT02044796

Outpatient Induction Chemotherapy for Newly Diagnosed AML or MDS (7910)
Feasibility of Outpatient Induction Chemotherapy for Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Investigator: Pamela S. Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT01807091

Decitabine and Cytarabine for Newly Diagnosed AML, High Risk MDS or MPN (9019)
Decitabine plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Investigator: Pamela Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MDS);    Status: Recruiting;   Study ID: NCT02121418

Depletion of T Cells From Allogeneic Stem Cell Grafts for the Prevention of GVHD (FHCRC-2222)
A Multi-center Phase II Study of Selective Depletion of CD45RA+ T cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

Investigator: Marie Bleakley, MD;   Conditions: Acute Lymphoid Leukemia (ALL);, Acute Myeloid Leukemia (AML), Hematologic Malignancies, Myelodysplastic Syndromes (MDS) Myeloproliferative Syndromes (MPD);    Status: Recruiting;   Study ID: NCT00914940

Decitabine Followed by Idarubicin and Cytarabine for AML or MDS
Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML

Investigator: Derek L. Stirewalt, MD;   Conditions: Leukemia, Myelodysplastic Syndromes;    Status: Recruiting;   Study ID: NCT01607645

Decitabine + Mitoxantrone Hydrochloride, Etoposide, and Cytarabine for AML or MDS (2652)
Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase I/II Study

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes;    Status: Recruiting;   Study ID: NCT01729845

Tosedostat with Cytarabine or Decitabine for AML
A Phase II Study of Tosedostat in Combination With Either Cytarabine or Decitabine in Newly Diagnosed AML or High-Risk MDS

Investigator: John M. Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01567059

Radioimmunotherapy + SCT for Advanced AML, ALL, or MDS
Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate

Investigator: John M. Pagel, MD;   Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT00988715

Adoptive Immunotherapy for Relapsed AML, MDS, or CML (FH 2498)
Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-specific T Cell Receptor for Patients With High Risk or Relapsed AML, MDS, or CML

Investigator: Merav Bar, MD;   Conditions: Acute Myeloid Leukemia (AML); Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Leukemia;    Status: Recruiting;   Study ID: NCT01640301

AMG 232 for Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Investigator: Pamela Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT02016729